

W Katherine Yih

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/40350/publications.pdf>

Version: 2024-02-01

18
papers

967
citations

687363

13
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

1037
citing authors

#	ARTICLE	IF	CITATIONS
1	A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine. American Journal of Epidemiology, 2022, 191, 957-964.	3.4	7
2	A Broad Safety Assessment of the 9-Valent Human Papillomavirus Vaccine. American Journal of Epidemiology, 2021, 190, 1253-1259.	3.4	10
3	Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results. PLoS Medicine, 2019, 16, e1002844.	8.4	18
4	Comment on Sarathkumara et al.: Exposure to Hantavirus is a Risk Factor Associated with Kidney Diseases in Sri Lanka: A Cross Sectional Study. Viruses, 2019, 11, 1147.	3.3	0
5	Investigating Possible Infectious Causes of Chronic Kidney Disease of Unknown Etiology in a Nicaraguan Mining Community. American Journal of Tropical Medicine and Hygiene, 2019, 101, 676-683.	1.4	21
6	Yih et al. Respond to "Moving From Evidence to Impact for Human Papillomavirus Vaccination". American Journal of Epidemiology, 2018, 187, 1281-1281.	3.4	0
7	Assessment of Quadrivalent Human Papillomavirus Vaccine Safety Using the Self-Controlled Tree-Temporal Scan Statistic Signal-Detection Method in the Sentinel System. American Journal of Epidemiology, 2018, 187, 1269-1276.	3.4	29
8	Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females. Vaccine, 2016, 34, 172-178.	3.8	24
9	Intussusception Risk after Rotavirus Vaccination in U.S. Infants. New England Journal of Medicine, 2014, 370, 503-512.	27.0	276
10	Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP/IPV) vaccine. Vaccine, 2014, 32, 3019-3024.	3.8	36
11	Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine, 2013, 31, 2578-2583.	3.8	47
12	Surveillance for Adverse Events Following Receipt of Pandemic 2009 H1N1 Vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. American Journal of Epidemiology, 2012, 175, 1120-1128.	3.4	62
13	Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink Project. Pediatrics, 2011, 127, S54-S64.	2.1	110
14	Evaluating Real-Time Syndromic Surveillance Signals from Ambulatory Care Data in Four States. Public Health Reports, 2010, 125, 111-120.	2.5	31
15	An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine, 2009, 27, 4257-4262.	3.8	82
16	The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health, 2005, 5, 68.	2.9	180
17	National Bioterrorism Syndromic Surveillance Demonstration Program. MMWR Supplements, 2004, 53, 43-9.	35.0	10
18	Attitudes of healthcare workers in U.S. hospitals regarding smallpox vaccination. BMC Public Health, 2003, 3, 20.	2.9	24